A Decision Guide for a Ketamine Consultation: Evidence, Alternatives, and Goals

A useful ketamine consultation should leave a person better informed even if the decision is not to begin treatment. It is an opportunity to clarify the diagnosis, review previous care, understand the proposed intervention, and examine practical barriers. It should not feel like a sales appointment in which uncertainty is treated as an obstacle to overcome. This guide offers a decision framework rather than recommending ketamine for any individual reader.

The central question is not whether ketamine can help depression in some circumstances. Published trials support antidepressant effects in particular populations and treatment settings. The more useful question is whether the proposed treatment, delivered by this team, addresses this person's needs with an acceptable balance of expected benefit, risk, burden, and alternatives. Answering it requires more detail than a general success rate or an account of a dramatic session.

Clarify the problem being treated

Ask the clinician to explain the working diagnosis and the symptoms the treatment is intended to address. Depression can occur in different conditions, and treatment decisions may change with a history of mania, psychosis, substance-related problems, or significant medical illness. A consultation should explore those possibilities rather than assuming that a high depression score establishes every aspect of the diagnosis. Screening forms can support, but not replace, a clinical assessment.

Bring a history of previous treatments, including approximate duration, adherence, benefit, adverse effects, and reasons for stopping. An unsuccessful trial may have been limited by tolerability or access rather than a clear lack of efficacy. The phrase treatment resistant should not erase those distinctions. If records are incomplete, say so. A clinician can help reconstruct the history and identify which uncertainties matter to the next decision.

Identify the exact product and route

Ask whether the proposal involves IV racemic ketamine, esketamine nasal spray, or a compounded preparation using another route. These are not interchangeable names for a single evidence base. Route affects absorption, administration, monitoring, and which studies are directly applicable. A clinic should identify the medication and explain the regulatory status of the proposed use without implying that approval of one formulation automatically validates another.

The Spravato prescribing information, FDA, 2025, dated 2025, lists adult treatment-resistant depression as an indication for esketamine alone or with an oral antidepressant. Its separate indication for depressive symptoms in adults with major depression and acute suicidal ideation or behavior requires an oral antidepressant. Those distinctions matter. The label also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Do not treat the broad phrase FDA approved as a complete explanation.

Read the evidence at the right time scale

The Murrough et al., single-infusion ketamine randomized trial, 2013 compared a single ketamine infusion with midazolam and assessed its primary depression outcome at 24 hours. That supports a rapid-effect question. It does not establish a universal multi-session package, a permanent cure, or the ideal maintenance frequency. When a clinic cites a study, ask which part of its proposed plan that study actually supports and which parts rely on less certain evidence or clinical judgment.

A treatment can have a real average effect while remaining uncertain for an individual. Ask about the population studied, the outcome definition, follow-up duration, and missing data. Our response-rate reading guide explains how those details change the meaning of a percentage. A statement of uncertainty is not necessarily a warning sign; inability or unwillingness to explain the uncertainty is more concerning.

Discuss alternatives without creating a competition

A consultation should consider appropriate medication strategies, psychotherapy, TMS, ECT, and other relevant care rather than presenting ketamine as the only serious option. The available choices depend on diagnosis, urgency, prior treatment, medical risks, preference, and access. The purpose is not to rank every intervention universally. It is to explain why the proposed next step fits the person's current situation better than plausible alternatives.

The Anand et al., ketamine versus ECT, 2023 was an open-label randomized noninferiority trial in nonpsychotic treatment-resistant major depression. Its findings should not be generalized to psychotic depression or every reason ECT is used. A clinic should be able to discuss that limit without turning the comparison into a blanket claim that one treatment has replaced the other. If urgency is high, a specialist may need to consider options and settings beyond a routine outpatient ketamine service.

Define meaningful benefit in advance

Choose goals that reflect both symptoms and daily life. Examples include less persistent despair, improved ability to eat and wash, or renewed participation in relationships. Avoid a goal such as never feeling sad again, which is neither realistic nor clinically specific. Ask which rating scale will be used, when reassessment will occur, and what amount of change would influence the decision to continue.

Our treatment-record guide shows how to combine symptom scores, functional observations, and adverse effects. Keeping those domains separate helps prevent a profound session from being mistaken for durable recovery or a difficult day from being mistaken for definitive failure. The clinician should interpret the pattern, including sleep, concurrent treatments, and medical changes, rather than relying on one isolated score.

Evaluate safety as a process

Ask who performs the medical and psychiatric assessment, who is present during treatment, and who makes discharge decisions. Monitoring should match the medication, route, patient, and setting. For esketamine, the dated FDA label requires at least two hours of observation and assessment of clinical stability before leaving. It warns about sedation, dissociation, respiratory depression, abuse and misuse, and other important risks. Familiarity with treatment does not remove those requirements.

Share a complete medication and substance-use history, cardiovascular conditions, urinary symptoms, and past unusual mood states. Do not stop medicines to improve eligibility or conceal information because travel and payment have already been arranged. A safe service should be able to explain postponement and escalation procedures. Specific clinical concerns may require communication with primary care, a specialist, or the person's usual psychiatric clinician before a decision can be made.

Separate acute treatment from continuation

Ask what happens if initial benefit is absent, partial, or short lived. A clear plan should describe reassessment rather than guaranteeing that everyone will eventually respond if enough sessions are purchased. It should also explain when additional evaluation or a different treatment would be considered. Prepaid packages can create pressure to continue despite uncertainty, so request the clinical and financial stopping rules before committing.

The Daly et al., esketamine relapse-prevention randomized trial, 2019 studied continuation among selected people who had already improved on esketamine with an oral antidepressant. It cannot establish the probability of benefit for every new starter or validate a maintenance schedule for another route. A continuation decision should weigh preserved benefit against adverse effects, practical burden, and ongoing uncertainty. It is a separate clinical question, not an automatic extension of the first appointment.

Confirm ownership of ongoing care

Find out who manages the depression between sessions and whether the ketamine service communicates with the usual clinician. A procedure-focused service may not provide comprehensive psychiatric care, and that distinction should be explicit. Ask how new suicidal thoughts, mood elevation, worsening substance use, or medical symptoms will be assessed. An emergency plan should not depend on the availability of the next routine appointment.

If there is immediate danger or an inability to remain safe, seek emergency care. In the United States, 988 provides crisis support; call 911 for an immediate life-threatening emergency. A ketamine consultation is not a substitute for urgent assessment. For nonurgent decisions, leave with written information about the proposed treatment, major uncertainties, alternatives, monitoring, follow-up, and expected costs. Taking time to review that information is a legitimate outcome of the consultation.

Turn uncertainty into a staged decision

Separate the decision to obtain an assessment from the decision to begin treatment, and separate both from a commitment to ongoing sessions. Each stage should add information. Before starting, ask which findings could change the recommendation and which questions remain unanswered. A clinician might need prior records, a medical review, or clarification of the diagnosis before a responsible recommendation is possible. Paying for an assessment should not imply that treatment is inevitable.

The existing trial evidence can organize those stages. The Murrough study addresses a rapid outcome after one infusion; the Daly study addresses relapse prevention among selected people who already benefited from esketamine with an oral antidepressant. Neither supplies a guaranteed personal trajectory from first appointment to maintenance. Ask the clinician to identify the evidence relevant to the decision being made today, rather than using continuation evidence to estimate the chance that a new patient will initially improve.

Also agree on how to evaluate an ambiguous result. Modest symptom change accompanied by substantial nausea, travel burden, or loss of work time may call for a different discussion than the same symptom change with restored daily functioning and little burden. A difficult session does not by itself establish failure, and an impressive immediate experience does not establish durable benefit. The next decision should use repeated clinical observations, adverse effects, functioning, and the person's priorities. Request a review date and a named clinician responsible for interpreting those findings before purchasing further treatment.

Medical disclaimer: This article provides general education, not diagnosis, individualized treatment advice, or emergency care. Evidence and regulatory statements refer to the dated sources cited, not an exhaustive verification of all changes through October 30, 2026.

Sources

1. Murrough et al., single-infusion ketamine randomized trial, 2013
2. Anand et al., ketamine versus ECT, 2023
3. Daly et al., esketamine relapse-prevention randomized trial, 2019
4. Spravato prescribing information, FDA, 2025